Compare HCSG & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCSG | AGIO |
|---|---|---|
| Founded | 1976 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | HCSG | AGIO |
|---|---|---|
| Price | $18.97 | $28.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $19.40 | ★ $36.25 |
| AVG Volume (30 Days) | 623.2K | ★ 1.3M |
| Earning Date | 02-11-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,808,303,000.00 | $44,791,000.00 |
| Revenue This Year | $9.23 | $27.83 |
| Revenue Next Year | $5.28 | $133.46 |
| P/E Ratio | $35.01 | ★ N/A |
| Revenue Growth | 6.26 | ★ 36.26 |
| 52 Week Low | $9.13 | $22.24 |
| 52 Week High | $20.26 | $46.00 |
| Indicator | HCSG | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 53.45 |
| Support Level | $18.80 | $26.25 |
| Resistance Level | $19.28 | $29.10 |
| Average True Range (ATR) | 0.54 | 1.09 |
| MACD | -0.04 | 0.27 |
| Stochastic Oscillator | 65.52 | 78.84 |
Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry. The company operates two business segments, both contributing roughly equally to the company's revenue: Housekeeping, laundry, linen, and other services; and Dietary department services. Housekeeping includes management of clients' housekeeping departments, cleaning, disinfecting and sanitizing, laundry, bed linen, and uniform services. Dietary consists of food purchasing, meal preparation, and providing dietitian consulting services. Its clients are nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States of America.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.